GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors

Nature Chemical Biology

Volumn 11, Issue 1, 2015, Pages 58-63

  Thorne, Curtis A ^a   Wichaidit, Chonlarat ^a   Coster, Adam D ^a   Posner, Bruce A ^b   Wu, Lani F ^a,c   Altschuler, Steven J ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; BETA CATENIN; DASATINIB; ERLOTINIB; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYC PROTEIN; RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DESENSITIZATION; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84927136638     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1690     Document Type: Article

References (40)

1. Doble, B.W. & Woodgett, J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186 (2003).
2. Kim, L. & Kimmel, A.R. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr. Opin. Genet. Dev. 10, 508-514 (2000).
3. Pap, M. & Cooper, G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J. Biol. Chem. 273, 19929-19932 (1998).
4. Sutherland, C. What are the bona fide GSK3 substrates? Int. J. Alzheimers Dis. 2011, 505607 (2011).
5. Farago, M. et al. Kinase-inactive glycogen synthase kinase 3β promotes Wnt signaling and mammary tumorigenesis. Cancer Res. 65, 5792-5801 (2005).
6. Kang, T. et al. GSK-3β targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3β inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13, 36-47 (2008).
7. Leis, H., Segrelles, C., Ruiz, S., Santos, M. & Paramio, J.M. Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis. Mol. Carcinog. 35, 180-185 (2002).
8. Zhang, H.H., Lipovsky, A.I., Dibble, C.C., Sahin, M. & Manning, B.D. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24, 185-197 (2006).
9. Zhou, B.P. et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931-940 (2004).
10. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
11. Knox, C. et al. DrugBank 3.0: a comprehensive resource foromics research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
12. Roig, A.I. et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology 138, 1012-21.e1-1012-21.e5 (2010).
13. Doble, B.W., Patel, S., Wood, G.A., Kockeritz, L.K. & Woodgett, J.R. Functional redundancy of GSK-3α and GSK-3β in Wnt/β-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev. Cell 12, 957-971 (2007).
14. Bennett, C.N. et al. Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 277, 30998-31004 (2002).
15. US National Cancer Institutes-National Institutes of Health. Synthetics and Pure Natural Products. Developmental Therapeutics Program NCI/NIH, http://dtp.nci.nih.gov/branches/dscb/oncology-drugset-explanation.html (2014).
16. Yost, C. et al. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454 (1996).
17. Liu, C. et al. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847 (2002).
18. Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128 (2004).
19. Sarbassov, D.D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302 (2004).
20. Efeyan, A. & Sabatini, D.M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 22, 169-176 (2010).
21. Sabatini, D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729-734 (2006).
22. Thoreen, C.C. & Sabatini, D.M. Rapamycin inhibits mTORC1, but not completely. Autophagy 5, 725-726 (2009).
23. O'Reilly, K.E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
24. Chen, C.H. et al. ER stress inhibits mTORC2 and Akt signaling through GSK-3beta-mediated phosphorylation of rictor. Sci. Signal. 4, ra10 (2011).
25. Huang, J. & Manning, B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222 (2009).
26. Thoreen, C.C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
27. Feldman, M.E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
28. Petronczki, M., Lenart, P. & Peters, J.M. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev. Cell 14, 646-659 (2008).
29. Rudolph, D. et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094-3102 (2009).
30. Olmos, D. et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 17, 3420-3430 (2011).
31. Schöffski, P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14, 559-570 (2009).
32. Zheng, H., Saito, H., Masuda, S., Yang, X. & Takano, Y. Phosphorylated GSK3β-Ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res. 27, 3561-3569 (2007).
33. Fiol, C.J. et al. Phosphoserine as a recognition determinant for glycogen synthase kinase-3: phosphorylation of a synthetic peptide based on the G-component of protein phosphatase-1. Arch. Biochem. Biophys. 267, 797-802 (1988).
34. Frame, S., Cohen, P. & Biondi, R.M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327 (2001).
35. Thomas, G.M. et al. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and β-catenin. FEBS Lett. 458, 247-251 (1999).
36. Tighe, A., Ray-Sinha, A., Staples, O.D. & Taylor, S.S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol. 8, 34 (2007).
37. Hertz, N.T. et al. A neo-substrate that amplifies catalytic activity of Parkinson's-disease-related kinase PINK1. Cell 154, 737-747 (2013).
38. Simpson, G.L., Hughes, J.A., Washio, Y. & Bertrand, S.M. Direct small-molecule kinase activation: novel approaches for a new era of drug discovery. Curr. Opin. Drug Discov. Devel. 12, 585-596 (2009).
39. Thorne, C.A. et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. Nat. Chem. Biol. 6, 829-836 (2010).
40. Coster, A.D., Wichaidit, C., Rajaram, S., Altschuler, S.J. & Wu, L.F. A simple image correction method for high-throughput microscopy. Nat. Methods 11, 602 (2014).